ELTX earnings date and last-quarter result: next report 2026-08-06, last quarter miss, P/E -1.32. Updated 2026-07-23.
Elicio Therapeutics (ELTX) Research Hub
Elicio Therapeutics (ELTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.7 USD (-10.53%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.32, market cap 0.06B. This hub links to the full technical, earnings and options research available for ELTX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.7 USD (-10.53%) |
| 52-week range | 1.44 USD – 6.64 USD |
| Trend regime | Range |
| 14-day RSI | 42.2 (Bearish) |
| Trailing P/E | -1.32 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ELTX
Covered Call on ELTX: how it works, illustrative setup around the real 1.7 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ELTX: how it works, illustrative setup around the real 1.7 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ELTX: how it works, illustrative setup around the real 1.7 USD price, max profit/loss, breakeven and when to use it. Educational.
ELTX technical analysis: range, last 1.7 USD, RSI 42.2, 52w range 1.44 USD–6.64 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ELTX in?
Elicio Therapeutics (ELTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ELTX in an uptrend or downtrend?
As of 2026-10-26, ELTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ELTX's trailing P/E ratio?
ELTX's trailing P/E is -1.32, with a market cap of 0.06B. See the earnings research page for full valuation detail.
When does ELTX next report earnings?
ELTX is next scheduled to report earnings on 2026-08-06.